Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ONO-2952 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| P | PLACEBO_COMPARATOR | - |
| E | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ONO-2952 | DRUG | 3 mg to 800 mg at a single dose; 10 mg and 200 mg for food effect study |
| Placebo | DRUG | Placebo dosed in the same manner as ONO-2952 |
Inclusion Criteria: * Healthy non-smoking male or female subjects (18-55 inclusive) * Body mass index (BMI) of 19-35 kg/m2 (inclusive) * For females, surgically sterilized, postmenopausal, or who are non- lactating and agree to use a double barrier method of contraception Exclusion Criteria: * Hi...
ONO-2952 is an investigational small molecule being studied in healthy adult subjects. It is not approved for any indication and is in early clinical development. The completed Phase 1 trial evaluated its safety, tolerability, and pharmacokinetics in healthy volunteers.
ONO-2952 is being developed by BrainsWay Ltd., a company traded under the ticker BWAY. The drug is in Phase 1 clinical development.
ONO-2952 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed.
ONO-2952 has one completed clinical trial, NCT01364441, a single-dose study evaluating safety, tolerability, and pharmacokinetics in healthy adult subjects. The trial enrolled 48 participants, was randomized, double-blind, and placebo-controlled, and was conducted in the United States.
ONO-2952 is not FDA approved. It is an investigational drug in Phase 1 clinical development. The completed trial was a Phase 1 study in healthy volunteers, and no approval status has been established.